Summit X LLC’s Charles River Laboratories CRL Stock Holding History

Summit X LLC’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-150	Closed	-$679	–	286
2020 Q3	$679	Buy	+150	New	+$31.1K	0.01%	275

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Summit X LLC's CRL Position: Q4 2020 in Review

Summit X LLC sold out of Charles River Laboratories (CRL) in Q4 2020, closing a stake of 150 shares — an estimated $679 sold.

Summit X LLC first reported a position in CRL in Q3 2020 and held it in 1 quarter. The position peaked at $679 in Q3 2020. 538 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

Summit X LLC reported no remaining Charles River Laboratories position as of Q4 2020 after selling out during the quarter.
Summit X LLC sold 150 Charles River Laboratories shares in Q4 2020, an estimated $679.
Summit X LLC first reported a position in Charles River Laboratories in Q3 2020 and held it in 1 quarter.
Summit X LLC's Charles River Laboratories position peaked at $679 in Q3 2020.
538 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Summit X LLC's 13F filing for Q4 2020, filed 29 Jan 2021.